0001104659-24-057525 8-K 14 20240506 7.01 9.01 20240506 20240506 Annovis Bio, Inc. 0001477845 2834 03 Life Sciences 262540421 DE 1231 8-K 34 001-39202 24918549 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 QR Pharma, Inc. 20091202 8-K 1 tm2413238d2_8k.htm FORM 8-K
false 0001477845 0001477845 2024-05-06 2024-05-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

  

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): May 6, 2024

 

  

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter) 

 

 

Delaware 001-39202 26-2540421

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

101 Lindenwood Drive, Suite 225
Malvern
, PA 19355

(Address of Principal Executive Offices, and Zip Code)

 

(484) 875-3192

Registrant’s Telephone Number, Including Area Code

 

                       Not Applicable                       

(Former Name or Former Address, if Changed Since Last Report) 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock, par value $0.0001 per share ANVS New York Stock Exchange

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 7.01 Regulation FD Disclosure

 

On May 6, 2024, Annovis Bio, Inc. (the “Company”) issued a press release dated May 6, 2024 which is being furnished as Exhibit 99.1 hereto.

 

Item 9.01   Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.    Description
99.1   Press Release Dated May 6, 2024
104   Cover Page Interactive Data File

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ANNOVIS BIO, INC.
     
Date: May 6, 2024 By: /s/ Maria Maccecchini
    Name: Maria Maccecchini
    Title: President and Chief Executive Officer

 

 

EX-99.1 2 tm2413238d2_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders

 

MALVERN, Pa. -- May 6, 2024 -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase II/III data from its Alzheimer’s study and sharing next steps.

 

Dear Friends,

 

The last few days have been very difficult. I received a lot of emails and phone calls that often expressed anger, uncertainty, and disappointment. Additionally, our results were questioned and criticized. This reaction not only caused a drastic drop in our share price, but, more importantly, it saddened the Annovis team. We are determined to develop a drug that treats Alzheimer’s (AD) and Parkinson’s diseases (PD) and makes the life of the afflicted people and their caretakers easier. However, every setback makes it harder to reach this goal.

 

At Annovis, we hold rigorous science, open communication, and transparency seriously, and it is our responsibility to conduct a clinical study in conformance with FDA guidelines and to the highest standards possible. In science, results are often less than perfect, but they pave the way for a better plan when designing and executing the next steps.

 

The Phase II/III study provided us with valuable information for an improved Phase III pivotal trial. First, we will prescreen patients for plasma AD biomarkers to confirm the diagnosis. Second, we will only enroll patients with early and mild Alzheimer’s (MMSE 21-28), the subpopulation which showed the highest level of improvement after buntanetap, as seen from our completed AD studies (Table 1).

 

Study AD patient #
Patients
Endpoint Duration Drug vs
Baseline
Drug vs
Placebo
Phase IIa; 2021 MMSE 18-28 14 ADAS-Cog11 1 month -4.4 -3.2
Phase II/III; 2024 MMSE 21-24 90 ADAS-Cog11 3 months -3.3 -2.36
Phase II/III; 2024 MMSE 14-20 112 ADAS-Cog11 3 months -0.65 1.79

 

Table 1. Summary of cognitive response to buntanetap at different disease stages measured in completed AD studies conducted by Annovis. The table clearly shows a strong response in patients with early AD (MMSE 18-28 and MMSE 21-24), while in moderate AD patients (MMSE 14-20), the response is obscured by high placebo effect.

 

The goal of the Phase II/III trial was to learn about the breadth of our drug’s efficacy and to obtain information for a pivotal disease-modifying study. This goal was achieved. We believe that the FDA will accept buntanetap for symptomatic relief and will allow us to continue with the next pivotal Phase III study for disease-modification.

 

 

 

 

About Buntanetap

 

Buntanetap (formerly known as Posiphen or ANVS401) attacks neurodegeneration by inhibiting the formation of multiple neurotoxic proteins - amyloid beta, tau, alpha synuclein, and TDP43 - thereby improving synaptic transmission, axonal transport and neuroinflammation. Dysregulation of these pathways has been shown to be the cause of nerve cell degeneration and ultimately death. By attacking these pathways, buntanetap has the ability to reverse neurodegeneration in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.

 

About Annovis Bio, Inc.

 

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and other chronic neurodegenerative diseases. The company believes it is the only company developing a drug for both AD and PD designed to inhibit more than one neurotoxic protein to restore axonal and synaptic activity. By improving brain function, the Company’s goal is to treat memory loss and dementia associated with AD as well as body and brain dysfunction associated with PD. For more information about Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter.

  

Forward-Looking Statements

 

This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation, the Company's plans related to clinical trials. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by forward-looking statements, including regarding patient enrollment, the effectiveness of buntanetap and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of buntanetap. See also additional risk factors set forth in the Company's periodic filings with the SEC, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. All forward-looking statements in this press release are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

  

Investor Contacts:

 

Maria Maccecchini, Ph.D.

 

maccecchini@annovisbio.com

 

 

 

EX-101.SCH 3 anvs-20240506.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 anvs-20240506_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 anvs-20240506_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
May 06, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 06, 2024
Entity File Number 001-39202
Entity Registrant Name ANNOVIS BIO, INC.
Entity Central Index Key 0001477845
Entity Tax Identification Number 26-2540421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 101 Lindenwood Drive
Entity Address, Address Line Two Suite 225
Entity Address, City or Town Malvern
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19355
City Area Code 484
Local Phone Number 875-3192
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ANVS
Security Exchange Name NYSE
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://annovisbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports anvs-20240506.xsd anvs-20240506_lab.xml anvs-20240506_pre.xml tm2413238d2_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2413238d2_8k.htm": { "nsprefix": "ANVS", "nsuri": "http://annovisbio.com/20240506", "dts": { "schema": { "local": [ "anvs-20240506.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "anvs-20240506_lab.xml" ] }, "presentationLink": { "local": [ "anvs-20240506_pre.xml" ] }, "inline": { "local": [ "tm2413238d2_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://annovisbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2413238d2_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2413238d2_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-057525-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-057525-xbrl.zip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end XML 17 tm2413238d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001477845 2024-05-06 2024-05-06 iso4217:USD shares iso4217:USD shares false 0001477845 8-K 2024-05-06 ANNOVIS BIO, INC. DE 001-39202 26-2540421 101 Lindenwood Drive Suite 225 Malvern PA 19355 484 875-3192 Common Stock, par value $0.0001 per share ANVS NYSE false false false false true false